cryptocurrency i- Top Top stories

Huaxin Securities: China Unicom's operating income grew steadily and maintained its "buy" rating. Huaxin Securities Research Report pointed out that since the beginning of this year, China Unicom (600050.SH) has seen steady growth in operating income, rapid improvement in profitability, steady expansion of user scale and continuous consolidation of network foundation, laying a more solid foundation for high-quality development of enterprises. Communication and digital intelligence services are driven by two wheels, injecting vitality into the company's performance. Looking forward to the whole year, the company will adhere to the general tone of steady progress, promote the network to be new, technology to be new and service to be new, strive to achieve the performance goal of steady growth of operating income and double-digit growth of profits throughout the year, take greater steps in high-quality development, and accelerate the construction of a world-class science and technology service enterprise with global competitiveness. With the gradual expansion of user scale and the drive of digital transformation, the company will benefit from the continuous improvement of revenue and profit and maintain the "buy" investment rating.South Korea's National Assembly passed "Yin Xiyue's General Special Inspection Law" and "Jin Jianxit's Inspection Law". The reporter of the General Station was informed that on the 12th local time, South Korea's National Assembly held a general meeting of parliamentarians and passed "Yin Xiyue's General Special Inspection Law" and "Jin Jianxit's Inspection Law". (CCTV News)Zhu Min, former vice president of IMF: Domestic consumption, manufacturing and green transformation will become the growth drivers of China's economy. Recently, at the China 2024 Annual Meeting and the 22nd Financial Billboard, Zhu Min, former vice president of China International Economic Exchange Center, said that one of the three traditional locomotives of China's economic growth is infrastructure investment; The second is the real estate industry, and the third is export. The transformation of the whole economic structure needs a new growth impetus. Zhu Min said that this new growth driver is, first, based on domestic consumption, and second, insisting on doing a good job in domestic manufacturing and doing high technology; The third is green transformation. We will continue to take the road of sustainable development of green transformation in China and improve our core competitiveness.

By 2029, China will build about 10,000 superior specialties of traditional Chinese medicine. According to state administration of traditional chinese medicine, China will promote the construction of superior specialties of traditional Chinese medicine at different levels to further improve the clinical efficacy of traditional Chinese medicine. By 2029, the overall scale of superior specialties of traditional Chinese medicine will reach about 10,000. Recently, state administration of traditional chinese medicine issued opinions on accelerating the construction of superior specialties of traditional Chinese medicine, and put forward the requirements of strengthening the planning and layout of superior specialties of traditional Chinese medicine and promoting the construction of superior clusters of traditional Chinese medicine. (CCTV News)Zelensky's office stated that it was ready to negotiate with Russia. Mikhail Podolyak, adviser to the director of Ukrainian President Zelensky's office, said in an interview with Channel 24 that Kiev was ready to negotiate with Russia. He pointed out that simple solutions should not be expected, and Ukraine needs just peace conditions. Earlier, Kremlin spokesman dmitry Peskov said that Russia was willing to negotiate with Ukraine provided that the conditions proposed by Russian President Vladimir Putin were met. The conditions mentioned include the complete withdrawal of Ukrainian troops from new Russian regions and Ukraine's neutrality.Shanghai Science and Technology Commission: Increase financial support for projects in the fields of scientific instruments, scientific research reagents and technical standards in the Action Plan for Scientific and Technological Innovation, and Shanghai Science and Technology Commission issued the Action Plan for Promoting the Innovative Development of Scientific Instruments and Scientific Research Reagents in Shanghai (2025-2027). The plan points out that financial input should be increased. We will increase support for projects in the fields of scientific instruments, scientific research reagents and technical standards in the Action Plan for Science and Technology Innovation, support technology research and development, product development and standard development, select and fund high-end scientific instruments and scientific research reagent products, and support the construction of technical test and verification platforms, application scenarios and user experience centers. 16. Strengthen financial support. Establish and improve the industrial venture capital mechanism, encourage and guide market capital to participate in industrial development. Give play to the role of the parent fund of the three leading industries and the future industrial fund, encourage social capital investment, support debt financing, mergers and acquisitions, and promote enterprises to become bigger and stronger.

In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for generic drug substitution. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)The Nikkei 225 index just broke through the 39,900.00 mark, and the latest report was 39,899.07, up 1.34% in the day.Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.